Novartis Shows Dynamic Momentum In Industry-Leading Pipeline
20. Januar 2005 01:09 ET
|
Novartis
BASEL, Switzerland, Jan. 20, 2005 (PRIMEZONE) --Novartis (NYSE:NVS):
* 75 projects in development, including 43 new molecular entities
* Key late-stage projects progressing on track
* New data...
Novartis: Diovan(R) Receives Approval in Sweden to Treat High-Risk Heart Attack Patients
01. Dezember 2004 01:30 ET
|
Novartis
BASEL, Switzerland, Dec. 1, 2004 (PRIMEZONE) -- First-in-class approval solidifies already established cardio-protective benefits of leading high blood pressure agent Paves the way for further...
Following EMEA decision to review safety of COX-2 class, Novartis temporarily withdraws EU Mutual Recognition Procedure application for Prexige(R)
30. November 2004 01:30 ET
|
Novartis
BASEL, Switzerland, Nov. 30, 2004 (PRIMEZONE) -- Novartis Pharma AG announced today that it has withdrawn the application for the EU Mutual Recognition Procedure for Prexige(R) (lumiracoxib) to await...
Novartis Responds to Request by French Market Authority
12. März 2004 01:59 ET
|
Novartis
BASEL, Switzerland, March 12, 2004 (PRIMEZONE) -- Responding to a request by AMF, the French market authority, Novartis AG confirms they are exploring the feasibility of a combination with Aventis....
Novartis Successfully Completes European Mutual Recognition Procedure for Myfortic(R) -- its New Immunosuppressant
10. Februar 2004 01:44 ET
|
Novartis
BASEL, Switzerland, Feb. 10, 2004 (PRIMEZONE) -- Novartis Pharma AG (NYSE:NVS) announced today that its application for the new enteric-coated immunosuppressant, Myfortic (mycophenolate sodium)...
Novartis Files Application for New Indication for Diovan
30. Januar 2004 01:37 ET
|
Novartis
BASEL, Switzerland, Jan. 30, 2004 (PRIMEZONE) -- Novartis Pharma AG announced it has filed an application to various regulatory authorities for a new indication for Diovana (valsartan) to improve...
Novartis 2003 Financial Results
22. Januar 2004 01:20 ET
|
Novartis
BASEL, Switzerland, Jan. 22, 2004 (PRIMEZONE) -- Novartis posts leading growth among top-ten pharmaceutical companies(1), sustaining double-digit increase in sales and operating income in...
Media Alert: Novartis 2003 Financial Results
20. Januar 2004 10:34 ET
|
Novartis
BASEL, Switzerland, Jan. 20, 2004 (PRIMEZONE) -- Please note that Novartis will publish its financial results for 2003 on Thursday, January 22, 2004 at approximately 7.15 a.m. (Swiss time) through...
Novartis to Acquire Worldwide Adult Medical Nutrition Business of Mead Johnson & Company, Strengthening its Number Two Global Position
16. Dezember 2003 01:37 ET
|
Novartis
BASEL, Switzerland, Dec. 16, 2003 (PRIMEZONE) -- Novartis:
-- Transaction offers Novartis entry to U.S. retail medical nutrition
channel and enhanced access to Japanese market
--...
Industry Leading Pipeline to Bring Novel Treatments to Patients and Sustain Above-Market Growth at Novartis
19. November 2003 00:40 ET
|
Novartis
BASEL, Switzerland, and NEW YORK, Nov. 19, 2003 (PRIMEZONE) -- Novartis:
New positive Phase II data on LAF237 (type-II diabetes), SPP100
(hypertension), AAE581 (osteoporosis) and QAB149 (asthma...